Clinical trials: in Belarus
Diabetes Mellitus, Type II
Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Glimepiride With or Without Metformin
This study will evaluate the safety and efficacy of dutogliptin in patients with type 2 diabetes mellitus (T2DM) who are receiving background therapy of glimepiride with or without metformin.
- Trial name
- NCT00947557
- Testing
- Dutogliptin
- Where
- 147 sites in United States, Belarus and 6 more
- Volunteers
- 677 people
- Sponsor
- Forest Laboratories
Type 2 Diabetes
Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment
Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to test the efficacy of once daily saxagliptin in renally impaired patients.
- Trial name
- NCT00614939
- Testing
- Saxagliptin
- Where
- 74 sites in United States, Belarus and 12 more
- Volunteers
- 572 people
- Sponsor
- AstraZeneca
Benign Prostatic Hypertrophy
Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Benign Prostatic Hypertrophy (BPH) is a common and bothersome condition of aging men. It is characterized by an enlargement of the prostate occurring in human male over the age of 50 which increases in prevalence with age, and…
- Trial name
- NCT00663858
- Testing
- Cetrorelix 78+78
- Where
- 54 sites in Belarus, Bulgaria and 8 more
- Volunteers
- 420 people
- Sponsor
- AEterna Zentaris
Acromegaly
Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients
The purpose of this study is to assess the safety profile of a new prolonged release formulation of octreotide acetate, C2L-OCT-01 PR, administered intra muscularly every 4, 5 or 6 weeks in acromegalic patients.
- Trial name
- NCT00642421
- Testing
- C2L-OCT-01 PR, 10 or 20 mg, C2L-OCT-01 PR, 20 mg
- Where
- 10 sites in United States, Belarus and 4 more
- Volunteers
- 40 people
- Sponsor
- Ambrilia Biopharma, Inc.
Acromegaly
Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients
The purpose of this study is to assess the safety profile of C2L-OCT-01 PR for up to an additional 96-week period in acromegalic patients who completed the C2L-OCT-01 PR-301 study.
- Trial name
- NCT00635765
- Testing
- C2L-OCT-01 PR 30 mg
- Where
- 6 sites in Belarus, Hungary and 4 more
- Volunteers
- 63 people
- Sponsor
- Ambrilia Biopharma, Inc.
Myocardial Infarction, Acute ST-Segment Elevation
Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis in Myocardial Infarction - Study 25 (ExTRACT-TIMI25)
The primary objective of the study is to determine whether enoxaparin compared to unfractionated heparin will reduce the composite endpoint of all-cause mortality and non-fatal myocardial re-infarction within 30 days after…
- Trial name
- NCT00077792
- Testing
- Enoxaparin sodium (XRP4563)
- Where
- 48 sites in United States, Argentina and 46 more
- Volunteers
- 20,506 people
- Sponsor
- Sanofi
Small Cell Lung Cancer
Study of Picoplatin Efficacy After Relapse
Picoplatin is a new type of platinum drug that has been investigated in several clinical trials, and may provide an improved safety profile over current treatment options.
- Trial name
- SPEAR (NCT00465491)
- Testing
- picoplatin, best supportive care
- Where
- 143 sites in Argentina, Belarus and 13 more
- Volunteers
- 399 people
- Sponsor
- Poniard Pharmaceuticals
Lupus Erythematosus, Systemic, Lupus Nephritis
Study of LJP 394 in Lupus Patients With History of Renal Disease
The primary purpose of this study is to determine whether abetimus sodium is more effective than placebo in delaying time to renal flare in SLE patients with a history of renal disease.
- Trial name
- ASPEN (NCT00089804)
- Testing
- abetimus sodium (LJP 394), Phosphate-buffered saline
- Where
- 201 sites in United States, Argentina and 28 more
- Volunteers
- 943 people
- Sponsor
- La Jolla Pharmaceutical Company
Acromegaly
Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients
The purpose of this study is to assess the biological safety and efficacy of using the drug, C2L-OCT-01 PR, 30 mg to treat acromegalic patients.
- Trial name
- NCT00616551
- Testing
- C2L-OCT-01 PR, 30 mg, Octreotide acetate prolonged release, 30 mg
- Where
- 6 sites in Belarus, Hungary and 4 more
- Volunteers
- 65 people
- Sponsor
- Ambrilia Biopharma, Inc.
Hypogonadism
Study of 3 Doses of ARD-0403 in Testosterone Deficient Men
The purpose of this study is to determine which dose, if any, results in testosterone levels within the normal range for men.
- Trial name
- ARD-0403-001 (NCT00597051)
- Testing
- ARD-0403
- Where
- Belarus
- Volunteers
- 42 people
- Sponsor
- Ardana Bioscience Ltd